Angiogenesis antagonists: Current clinical trials

Angiogenesis

Volumn 2, Issue 1, 1998, Pages 9-20

  Brem, Steven ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002853251     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009068807898     Document Type: Conference Paper

References (49)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1, 27-31.
2. Folkman J. Angiogenesis inhibitors: from laboratory to clinic. Cancer Invest 1997; 16, suppl 1, abstr 11, 14-15, in press.
3. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333, 1757-1763.
4. Casey R, Li W. Factors controlling ocular angiogenesis. Am J Ophthalmol 1997; 124, 521-529.
5. Li WW, Li VW, Casey R, Tsakayannnis D. Arterial gene therapy. Lancet 1996; 348, 1381.
6. Li VW, Li WW. Cyclosporine and angiogenesis in psoriasis. J Am Acad Dermatol 1996; 35, 1019-1020.
7. Isner JM. Angiogenesis for revascularization of ischaemic tissues. Eur Heart J 1997; 18, 1-2.
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91, 4082-4085.
9. Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64, 971-978.
10. DeVore RF, Hellerqvist CG, Wakefield GB, et al. Phase I study of the antineovascularization drug CM101. Clin Cancer Res 1997; 3, 365-372.
11. Johnson DH, Wang Y-F, Hellerqvist CG. Soluble E-selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting anti-neovascularization agent, evaluated in phase 1 clinical trial. J Cancer Res Clin Oncol 1997; in press.
12. Thurman GB, Page DL, Wamil BD, et al. Acute inflammatory changes in subcutaneous microtumors in mice ears induced by intravenous CM101 (GBS Toxin). J Cancer Res Clin Oncol 1996; 122, 549-553.
13. Masiero L, Figg WD, Kohn EC. New anti-angiogenesis agents: review of the clinical experience with CAI, thalidomide, TNP-470 and interleukin-12. Angiogenesis 1997; 1, 23-35.
14. Kohn EC, Figg WD, Sarosy GA, et al. Phase I trial of micronized formulation CAI: pharmacokinetics, clinical outcome, and comparison of formulations. J Clin Oncol 1997; 15, 1985-1993.
15. Kohn EC, Reed E, Sarosy E, et al. Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers. Cancer Res 1996; 56, 569-573.
16. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogs of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 1990; 348, 555-559.
17. Brem H, Ehrlich P, Tsakayannis D, Folkman J. Delay of wound healing by the angiogenesis inhibitor TNP-470. Surg Forum 1997; 48, 714-716.
18. Figg WD, Pluda JM, Lush RM, et al. The pharmacokinetics of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 1997; 17, 91-97.
19. Rasmussen HS, McCann PP. Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 1997; 75, 1.
20. Millar A, Brown PB. 360 patient metaanalysis of studies of marimastat: a novel matrix metalloproteinase inhibitor. Ann Oncol 1996; 7 (suppl 5), 123.
21. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Invest New Drugs 1997; 15, 61-75.
22. Ferrara N, Keyt B. Vascular endothelial growth factor: basic biology and clinical implications. EXS 1997; 79, 209-232.
23. Millauer B, Shawver LK, Plate KH, et al. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367, 576-679.
24. Strawn LM, Mann E, Elliger SS, et al. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-β receptor. J Biol Chem 1994; 269, 21215-21222.
25. Shawver LK, Lipson KE, Fong TAT, et al. Receptor tyrosine kinases as targets for inhibition of angiogenesis. Drug Discovery Today 1997; 2, 50-63.
26. Shawver LK, Schwartz DP, Mann E, et al. Inhibition of PDGF-mediated signal transduction and tumor growth by N-[4-Trifluoromethyl)phenyl 5-methyl-isoxazole-4carboxamidee. Clin Cancer Res 1997; 3, 1167-1177.
27. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 1997; 94, 10868-10872.
28. Wu Z, O'Reilly MS, Folkman J, et al. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophys Res Commun 1997; 236, 651-654.
29. Sim BK, O'Reilly MS, Liang H, et al. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57, 1329-1334.
30. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88, 277-285.
31. Fotsis T, Zhan Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature 1994; 368, 237-239.
32. O'Reilly MS, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2, 689-692.
33. Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem Pharmacol 1996; 52, 1057-1063.
34. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275, 547-550.
35. Burrows FJ, Thorpe PE. Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 1993; 90, 8996-9000.
36. Burrows FJ, Thorpe PE. Vascular targeting - a new approach to the therapy of solid tumors. Pharmacol Ther 1994; 64; 155-174.
37. Denenkamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metast Rev 1990; 9, 267-282.
38. Moore KS, Wehrli S, Roder H, et al. Squalamine: an aminosterol antibiotic from the shark. Proc Natl Acad Sci USA 1993; 90, 1354-1358.
39. Tuszynski GP, Nicosia RF. Localization of thrombospondin and its CSVTCG-specific receptor in human breast carcinoma. Lab Invest 1994; 70, 228-233.
40. Albo D, Solomon MP, Granick MS, Rothman VL, Tuszynski GP. Thrombospondin (TSP) and transforming growth factor-β1 (TGF-β) promote human lung carcinoma A549 lung carcinoma cell plasminogen inhibitor type 1 (PAI-1) production and stimulate tumor cell attachment in vitro. Biochem Biophys Res Commun 1994; 203, 857-865.
41. Wang TN, Qian X, Granick MS, et al. Inhibition of breast cancer progression by an antibody to a thrombospondin-1 (TSP-1) receptor. Surgery 1996; 120, 449-454.
42. Tuszynski GP, Nicosia RF. The role of thrombospondin in tumor progression and angiogenesis. BioEssays 1996; 18; 71-76.
43. Donahue JK, Kikkawa K, Johns DC, Marban E, Lawrence JH. Ultrarapid, highly efficient viral gene transfer to the heart. Proc Natl Acad Sci USA 1997; 94, 4664-4668.
44. Takeshita S, Weir L, Chen D, et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996; 227, 628-635.
45. Tsurumi Y, Takeshita S, Chen D, et al. Direct intramuscular gene transfer of naked DNA encoding vascular endothelial growth factor augments collateral development and tissue perfusion. Circulation 1996; 94, 3281-3290.
46. Feldman LJ, Pastore CJ, Aubailly N, et al. Improved efficiency of arterial gene transfer by use of poloxamer 407 as a vehicle for adenoviral vectors. Gene Ther 1997; 4, 189-198.
47. Weissinger J. Pharmacology and toxicology of novel drug delivery systems. Regulatory issues. Drug Safety 1990; 5, Suppl 1, 107-113.
48. Weissinger J. Clinical pathology testing in preclinical safety assessment: regulatory concerns. Toxicol Pathol 1992; 20, 509-512.
49. Takano S, Gately S, Neville ME, et al. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res 1994; 54, 2654-2660.